Shots:

• The companies collaborated to get a new version of the BlueStar insulin management app that integrates insulin dosing data for several of Lilly’s insulins
• If approved- Lilly plans to commercialize the initial pen platform in the US and will evaluate opportunities to launch it in other geographies while Welldoc will continue to separately commercialize the BlueStar app. Lilly plans to submit to the FDA in 2021 for the data transfer module and Welldoc in 2021 for the new app
• The BlueStar is an app for adults with T1D & T2D. It is designed to integrate with a range of blood sugar readers and continuous glucose monitoring systems

 ­ Ref: Lilly | Image: Independent Balkan News Agency